Recruiting Myeloproliferative Neoplasms Studies in New York
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients....
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofi...
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on ...
Study to Assess SLN124 in Patients With Polycythemia Vera
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to ...
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test diffe...
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thro...
Study of Canakinumab in Patients With Myelofibrosis
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible pat...
About Myeloproliferative Neoplasms Clinical Trials in New York
Myeloproliferative neoplasms (MPNs) are blood cancers in which the bone marrow overproduces red blood cells, platelets, or white blood cells. Types include polycythemia vera, essential thrombocythemia, and myelofibrosis. Treatment depends on the specific type and risk factors.
There are currently 7 myeloproliferative neoplasms clinical trials recruiting participants in New York, NY. These studies are seeking a combined 630 participants. Research is being sponsored by Italfarmaco, Disc Medicine, Inc, Karyopharm Therapeutics Inc and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Myeloproliferative Neoplasms Clinical Trials in New York — FAQ
Are there myeloproliferative neoplasms clinical trials in New York?
Yes, there are 7 myeloproliferative neoplasms clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New York?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.
Are clinical trials in New York free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.
What myeloproliferative neoplasms treatments are being tested?
The 7 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for myeloproliferative neoplasms.
Data updated March 2, 2026 from ClinicalTrials.gov